Companies
BLIS Technologies
the strain-science pioneer — Streptococcus salivarius K12 and M18, with four new peer-reviewed studies landed in the first half of 2026.
- Country
- NZ
Commercial
Flagship S. salivarius K12/M18 oral probiotic strains (NZ origin, bacteriocin-producing); K12 breath/upper-respiratory, M18 caries; four new peer-reviewed studies H1 2026
Coverage
| CN | EU | US | |
|---|---|---|---|
| specialty-fine-chem | ✓ | ✓ | ✓ |
Regulatorsfdaefsanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | 6 prior funding rounds | media.businessdesk.co.nz · new.nzx.com · nzx.com |
| Capacity | Probi has full-scale production capacity of both bulk powder and product applications of BLIS K12 and BLIS M18 strains in Redmond, Washington | probi.com |
| Certification | B Corp certification and MyGreen Lab certification maintained | blis.co.nz · media.businessdesk.co.nz |
| Regulatory approval | US GRAS status held by BLIS K12 and BLIS M18 | blis.co.nz |
| Production site | Dunedin, New Zealand (manufacturing site) | aeroleads.com · blis.co.nz |
| Headcount | approximately 32 employees | aeroleads.com |
| Revenue | $14.7 million for the year ended 31 March 2026 | media.businessdesk.co.nz · new.nzx.com · nzx.com |
Independent sources: aeroleads.com · media.businessdesk.co.nz · new.nzx.com · nzx.com · probi.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Probiotic oral care | specialty-fine-chem | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.